rs1131690985
Variant summary
Our verdict is Pathogenic. The variant received 20 ACMG points: 20P and 0B. PS1PM1PM2PP3_StrongPP5_Very_Strong
The NM_000264.5(PTCH1):c.3499G>A(p.Gly1167Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 14/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in ClinVar. Synonymous variant affecting the same amino acid position (i.e. G1167G) has been classified as Likely benign.
Frequency
Consequence
NM_000264.5 missense
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 20 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | ENST00000331920.11 | c.3499G>A | p.Gly1167Arg | missense_variant | Exon 21 of 24 | 5 | NM_000264.5 | ENSP00000332353.6 | ||
| PTCH1 | ENST00000437951.6 | c.3496G>A | p.Gly1166Arg | missense_variant | Exon 21 of 24 | 5 | NM_001083603.3 | ENSP00000389744.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1
Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PTCH1 protein function. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1167 of the PTCH1 protein (p.Gly1167Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with basal cell nevus syndrome (PMID: 10890722, 15712338, 18502968; Invitae). ClinVar contains an entry for this variant (Variation ID: 428838). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.G1167R variant (also known as c.3499G>A), located in coding exon 21 of the PTCH1 gene, results from a G to A substitution at nucleotide position 3499. The glycine at codon 1167 is replaced by arginine, an amino acid with dissimilar properties. This alteration has been detected in multiple patients meeting clinical diagnostic criteria for nevoid basal cell carcinoma syndrome (NBCCS) (Barreto, DC et al. J Dent Res. 2000 Jun;79(6):1418-22; Pastorino, L et al. Hum Mutat. 2005 Mar;25(3):322-3). In one study, this alteration was detected in a 42-year-old male with NBCCS who had a history of multiple jaw keratocyts, BCCs, and palmar/plantar pits, and the alteration was reportedly found to segregate with disease in the family (Sun, LS et al. J Dent Res. 2008 Jun;87(6):575-9). This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.47% (greater than 200 alleles tested) in our clinical cohort. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at